Author: AEON Biopharma Inc

Posted Date:

April 6, 2026

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Inc

April 6, 2026
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma Inc

April 3, 2026
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

AEON Biopharma Inc

March 31, 2026
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program

AEON Biopharma Inc

March 25, 2026
AEON Biopharma Appoints John Bencich as Chief Financial Officer

AEON Biopharma Inc

March 9, 2026
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

AEON Biopharma Inc

March 5, 2026
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

AEON Biopharma Inc

January 27, 2026